Riccardo Lencioni

University of Pisa — Italy

Medicine · Health Sciences

83h-index45.0kcitations521works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(317), Liver Disease Diagnosis and Treatment(133), Liver Disease and Transplantation(54), Lung Cancer Treatments and Mutations(37), MRI in cancer diagnosis(37)

Publications518 total

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma Definitive Therapy: Counterpoint—Ablation Remains the Standard of Care
American Journal of Roentgenology·2026
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings
La radiologia medica·2025
Diagnostic Role of Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations
2025Open Access
Undertreated Volume and Tumor Morphology as Predictors of Outcome Following Thermal Ablation of 3–7-cm Hepatocellular Carcinoma
Journal of Vascular and Interventional Radiology·2025Open Access
Myocardial Extracellular Volume Measured from ECG-Ungated Whole-Body CT Examinations as an Early Biomarker of Chemotherapy-Induced Cardiotoxicity: Preliminary Findings
Preprints.org·2025Open Access
Estimation of tumor coverage after RF ablation of hepatocellular carcinoma using single 2D image slices
International Journal of Computer Assisted Radiology and Surgery·2025· 2 citedOpen Access
399: OUTCOMES BY KEY PROGNOSTIC FACTORS IN EMERALD-1: A PHASE 3 STUDY OF DURVALUMAB ± BEVACIZUMAB WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PARTICIPANTS WITH EMBOLIZATIONELIGIBLE UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology·2025
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy
European Heart Journal - Cardiovascular Imaging·2025· 2 cited
Abstract No. 236 Outcomes by Key Prognostic Factors in EMERALD-1: A Phase 3 Study of Durvalumab ± Bevacizumab with Transarterial Chemoembolization (TACE) in Participants with Embolization-Eligible Unresectable Hepatocellular Carcinoma (uHCC)
Journal of Vascular and Interventional Radiology·2025Open Access
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy
CINECA IRIS Institutional Research Information System (Sant'Anna School of Advanced Studies)·2025Open Access
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet·2025· 153 citedOpen Access
199P Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024
1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma
Regular and Young Investigator Award Abstracts·2024Open Access
Radiomics-based machine learning role in differential diagnosis between small renal oncocytoma and clear cells carcinoma on contrast-enhanced CT: A pilot study
European Journal of Radiology Open·2024· 3 citedOpen Access
mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma
International Journal of Radiation Oncology*Biology*Physics·2024· 1 cited
950P Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024Open Access
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 1 cited
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 6 cited
REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.
Journal of Clinical Oncology·2024· 5 cited
166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 1 citedOpen Access
page 1 of 26Next →

Frequent Co-authors

Carlo Bartolozzi(14), Josep M. Llovet(11), Thierry de Baère(8), Laura Crocetti(7), Masatoshi Kudo(7), Dania Cioni(6), Jordi Bruix(5), Luigi Solbiati(5), Michael C. Soulen(5), Won Young Tak(5), Minhua Chen(4), Damian E. Dupuy(4), A. Gillams(4), Riad Salem(4), Jeong Heo(4), Richard S. Finn(3), Morris Sherman(3), Andrew X. Zhu(3), Johannes Lämmer(3), Thomas J. Vogl(3)